AWM Investment Company Inc. Purchases 499,992 Shares of MDxHealth SA $MDXH

Key Points

• AWM Investment Company Inc. increased its stake in MDxHealth SA by 10.6%, owning 5,221,282 shares valued at approximately $7.41 million as of its latest SEC filing.
• Several analysts have assigned buy ratings to MDxHealth, with a consensus price target of $7.00 and recent upgrades indicating growing confidence in the company's stock.
• MDxHealth reported disappointing earnings, posting a loss of ($0.15) per share for the latest quarter, missing expectations, and guiding for similar performance in Q2 2025.

AWM Investment Company Inc. increased its holdings in shares of MDxHealth SA (NASDAQ:MDXH - Free Report) by 10.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,221,282 shares of the company's stock after buying an additional 499,992 shares during the period. AWM Investment Company Inc. owned 11.04% of MDxHealth worth $7,414,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Geode Capital Management LLC bought a new stake in MDxHealth in the fourth quarter valued at approximately $25,000. Castleview Partners LLC bought a new stake in MDxHealth in the first quarter valued at approximately $48,000. Delta Investment Management LLC bought a new stake in MDxHealth in the fourth quarter valued at approximately $81,000. Renaissance Technologies LLC increased its stake in MDxHealth by 715.2% in the fourth quarter. Renaissance Technologies LLC now owns 123,100 shares of the company's stock valued at $292,000 after purchasing an additional 108,000 shares in the last quarter. Finally, Northern Trust Corp bought a new stake in MDxHealth in the fourth quarter valued at approximately $1,033,000.

Wall Street Analyst Weigh In

MDXH has been the subject of several recent analyst reports. Craig Hallum initiated coverage on shares of MDxHealth in a research note on Thursday, July 17th. They issued a "buy" rating and a $8.00 target price for the company. Wall Street Zen raised shares of MDxHealth to a "hold" rating in a research report on Saturday, August 30th. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $7.00.

MDxHealth Price Performance

MDXH remained flat at $3.53 during trading hours on Monday. 35,017 shares of the company traded hands, compared to its average volume of 92,896. MDxHealth SA has a fifty-two week low of $1.35 and a fifty-two week high of $3.81. The firm has a fifty day moving average price of $2.71 and a 200-day moving average price of $2.11. The company has a market capitalization of $166.93 million, a PE ratio of -4.03 and a beta of 1.48. The company has a debt-to-equity ratio of 13.81, a quick ratio of 1.22 and a current ratio of 1.31.

MDxHealth (NASDAQ:MDXH - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02). MDxHealth had a negative return on equity of 374.98% and a negative net margin of 34.98%.The business had revenue of $26.60 million for the quarter, compared to analyst estimates of $26.60 million. MDxHealth has set its Q2 2025 guidance at -0.150--0.150 EPS. On average, equities research analysts anticipate that MDxHealth SA will post -1.15 EPS for the current year.

MDxHealth Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.